Specifically, the high expression of STEAP1 in patients with stage I lung cancer was associated with poor prognosis, and the low expression of STEAP2 in patients with stage I lung cancer was associated with poor prognosis, both of which were statistically significant (P < 0.05). Here, STEAP2 is linked to lung carcinoma.